Hutchmed (china) Limited (HCM) Share Price & Analysis

Open: 173.00
High: 173.00
Low: 172.00
Close: 172.00
Change: -5.50 (-3.12%)
Volume: 1,913

Market Cap: £1.50bn
1Y Performance: -0.3%
Avg Daily Volume: 35.5K

52-Week Range

150.48(22 Jun 26)292.00(29 Jul 25)

Current 172.00 · position in 52-week range

Dr. Dan ELDARChairman and Non-executive Director

–

Mr. Johnny CHENGExecutive Director, Acting Chief Executive Officer and Chief Financial Officer

–

Dr. Weiguo SUExecutive Director, Chief Executive Officer and Chief Scientific Officer

–

Ms. Edith SHIHNon-executive Director and Company Secretary

–

Mr. WONG Tak Wai

–

Hutchmed (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates in the commercial stage, with its first three medicines marketed in China and one approved in multiple international markets, including the US, Europe, and Japan. Hutchmed aims to bring drug candidates from in-house discovery to patients globally.

Industry: Health Care
Sector: Health Care
LEI: 2138006X34YDQ6OBYE79
Issuer: Hutchmed (China) Limited
Region: North America
Admission date: 19 May 2006
Website: www.hutch-med.com
X: @hutchmed

Shares in issue: 872,327,620
Total Voting Rights: 872,327,620

Last updated: 29 July 2026

ISIN: KYG4672N1198
Exchange: AIMX
Market: Aim
Market Segment: AMSM
Market Sector: ASM6

Open: 173.00
High: 173.00
Low: 172.00
Close: 172.00
Change: -5.50 (-3.12%)
Volume: 1,913

Market Cap: £1.50bn
1Y Performance: -0.3%
Avg Daily Volume: 35.5K

52-Week Range

150.48(22 Jun 26)292.00(29 Jul 25)

Current 172.00 · position in 52-week range

Dr. Dan ELDARChairman and Non-executive Director

–

Mr. Johnny CHENGExecutive Director, Acting Chief Executive Officer and Chief Financial Officer

–

Dr. Weiguo SUExecutive Director, Chief Executive Officer and Chief Scientific Officer

–

Ms. Edith SHIHNon-executive Director and Company Secretary

–

Mr. WONG Tak Wai

–

Industry: Health Care
Sector: Health Care
LEI: 2138006X34YDQ6OBYE79
Issuer: Hutchmed (China) Limited
Region: North America
Admission date: 19 May 2006
Website: www.hutch-med.com
X: @hutchmed

Shares in issue: 872,327,620
Total Voting Rights: 872,327,620

Last updated: 29 July 2026

ISIN: KYG4672N1198
Exchange: AIMX
Market: Aim
Market Segment: AMSM
Market Sector: ASM6

Open: 173.00
High: 173.00
Low: 172.00
Close: 172.00
Change: -5.50 (-3.12%)
Volume: 1,913

Market Cap: £1.50bn
1Y Performance: -0.3%
Avg Daily Volume: 35.5K

52-Week Range

150.48(22 Jun 26)292.00(29 Jul 25)

Current 172.00 · position in 52-week range

Dr. Dan ELDARChairman and Non-executive Director

–

Mr. Johnny CHENGExecutive Director, Acting Chief Executive Officer and Chief Financial Officer

–

Dr. Weiguo SUExecutive Director, Chief Executive Officer and Chief Scientific Officer

–

Ms. Edith SHIHNon-executive Director and Company Secretary

–

Mr. WONG Tak Wai

–

Industry: Health Care
Sector: Health Care
LEI: 2138006X34YDQ6OBYE79
Issuer: Hutchmed (China) Limited
Region: North America
Admission date: 19 May 2006
Website: www.hutch-med.com
X: @hutchmed

Issuer	Mkt cap	1Y
HCMHutchmed (china) Limited	£1.50bn	-0.3%
AMS Advanced Medical Solutions Group plc	£615m	+0.4%
AGY Allergy Therapeutics plc	£317m	-0.4%
AVCT Avacta Group plc	£311m	+0.4%
ANCR Animalcare Group plc	£231m	+0.2%
ANP Anpario plc	£107m	+0.4%

Peers in Health Care, ranked by comparable market cap. 1Y = trailing share-price change.

Shares in issue: 872,327,620
Total Voting Rights: 872,327,620

Last updated: 29 July 2026

ISIN: KYG4672N1198
Exchange: AIMX
Market: Aim
Market Segment: AMSM
Market Sector: ASM6

Open: 173.00
High: 173.00
Low: 172.00
Close: 172.00
Change: -5.50 (-3.12%)
Volume: 1,913

Market Cap: £1.50bn
1Y Performance: -0.3%
Avg Daily Volume: 35.5K

52-Week Range

150.48(22 Jun 26)292.00(29 Jul 25)

Current 172.00 · position in 52-week range

Dr. Dan ELDARChairman and Non-executive Director

–

Mr. Johnny CHENGExecutive Director, Acting Chief Executive Officer and Chief Financial Officer

–

Dr. Weiguo SUExecutive Director, Chief Executive Officer and Chief Scientific Officer

–

Ms. Edith SHIHNon-executive Director and Company Secretary

–

Mr. WONG Tak Wai

–

Industry: Health Care
Sector: Health Care
LEI: 2138006X34YDQ6OBYE79
Issuer: Hutchmed (China) Limited
Region: North America
Admission date: 19 May 2006
Website: www.hutch-med.com
X: @hutchmed

Issuer	Mkt cap	1Y
HCMHutchmed (china) Limited	£1.50bn	-0.3%
AMS Advanced Medical Solutions Group plc	£615m	+0.4%
AGY Allergy Therapeutics plc	£317m	-0.4%
AVCT Avacta Group plc	£311m	+0.4%
ANCR Animalcare Group plc	£231m	+0.2%
ANP Anpario plc	£107m	+0.4%

Peers in Health Care, ranked by comparable market cap. 1Y = trailing share-price change.

Shares in issue: 872,327,620
Total Voting Rights: 872,327,620

Last updated: 29 July 2026

ISIN: KYG4672N1198
Exchange: AIMX
Market: Aim
Market Segment: AMSM
Market Sector: ASM6

Issuer	Mkt cap	1Y
HCMHutchmed (china) Limited	£1.50bn	-0.3%
AMS Advanced Medical Solutions Group plc	£615m	+0.4%
AGY Allergy Therapeutics plc	£317m	-0.4%
AVCT Avacta Group plc	£311m	+0.4%
ANCR Animalcare Group plc	£231m	+0.2%
ANP Anpario plc	£107m	+0.4%

Peers in Health Care, ranked by comparable market cap. 1Y = trailing share-price change.

Issuer	Mkt cap	1Y
HCMHutchmed (china) Limited	£1.50bn	-0.3%
AMS Advanced Medical Solutions Group plc	£615m	+0.4%
AGY Allergy Therapeutics plc	£317m	-0.4%
AVCT Avacta Group plc	£311m	+0.4%
ANCR Animalcare Group plc	£231m	+0.2%
ANP Anpario plc	£107m	+0.4%

Peers in Health Care, ranked by comparable market cap. 1Y = trailing share-price change.

2 Jul 2026	09:30:00	HUTCHMED Announces NMPA Approval for ORPATHYS
30 Jun 2026	09:30:00	HUTCHMED to Announce 2026 Half-Year Results
29 Jun 2026	09:30:00	Announcement on blocklisting six monthly return
25 Jun 2026	07:00:08	HUTCHMED Highlights Phase II Data at ESMO
12 Jun 2026	07:00:06	HUTCHMED Highlights Sovleplenib Phase III Data

2 Jul 2026	09:30:00	HUTCHMED Announces NMPA Approval for ORPATHYS
30 Jun 2026	09:30:00	HUTCHMED to Announce 2026 Half-Year Results
29 Jun 2026	09:30:00	Announcement on blocklisting six monthly return
25 Jun 2026	07:00:08	HUTCHMED Highlights Phase II Data at ESMO
12 Jun 2026	07:00:06	HUTCHMED Highlights Sovleplenib Phase III Data

2 Jul 2026	09:30:00	HUTCHMED Announces NMPA Approval for ORPATHYS
30 Jun 2026	09:30:00	HUTCHMED to Announce 2026 Half-Year Results
29 Jun 2026	09:30:00	Announcement on blocklisting six monthly return
25 Jun 2026	07:00:08	HUTCHMED Highlights Phase II Data at ESMO
12 Jun 2026	07:00:06	HUTCHMED Highlights Sovleplenib Phase III Data

2 Jul 2026	09:30:00	HUTCHMED Announces NMPA Approval for ORPATHYS
30 Jun 2026	09:30:00	HUTCHMED to Announce 2026 Half-Year Results
29 Jun 2026	09:30:00	Announcement on blocklisting six monthly return
25 Jun 2026	07:00:08	HUTCHMED Highlights Phase II Data at ESMO
12 Jun 2026	07:00:06	HUTCHMED Highlights Sovleplenib Phase III Data

Hutchmed (china) Limited

Hutchmed (china) Limited

Price Chart

Key Statistics

Recent RNS announcements

Directors (10)

In the Press

Company details

Shares details

Instrument details

Price Chart

Key Statistics

Recent RNS announcements

Directors (10)

In the Press

Company details

Shares details

Instrument details

Price Chart

Key Statistics

Recent RNS announcements

Directors (10)

In the Press

Company details

Sector peers · Health Care

Shares details

Instrument details

Price Chart

Key Statistics

Recent RNS announcements

Directors (10)

In the Press

Company details

Sector peers · Health Care

Shares details

Instrument details

Sector peers · Health Care

Sector peers · Health Care